Cancer vaccines could be available by 2030, say scientists behind Covid jab

&Tab;&Tab;<div class&equals;"wpcnt">&NewLine;&Tab;&Tab;&Tab;<div class&equals;"wpa">&NewLine;&Tab;&Tab;&Tab;&Tab;<span class&equals;"wpa-about">Advertisements<&sol;span>&NewLine;&Tab;&Tab;&Tab;&Tab;<div class&equals;"u top&lowbar;amp">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;<amp-ad width&equals;"300" height&equals;"265"&NewLine;&Tab;&Tab; type&equals;"pubmine"&NewLine;&Tab;&Tab; data-siteid&equals;"111265417"&NewLine;&Tab;&Tab; data-section&equals;"1">&NewLine;&Tab;&Tab;<&sol;amp-ad>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;<&sol;div><p>Cancer vaccines could be accessible to patients within the next decade&comma; the husband and wife team behind one of the most successful Covid jabs has said&period;<&sol;p>&NewLine;<p>German couple Professors Ugur Sahin and Ozlem Tureci said they are hesitant to say they can find a cure for cancer&comma; but that they have had &OpenCurlyDoubleQuote;breakthroughs” they will keep working on&period;<&sol;p>&NewLine;<p>They said the development and success of the Pfizer&sol;BioNTech vaccine against Covid-19 which became widely rolled out in the pandemic &OpenCurlyDoubleQuote;gives back to our cancer work”&period;<&sol;p>&NewLine;<p>The couple – interviewed on BBC’s Sunday with Laura Kuenssberg programme – co-founded BioNTech in Mainz&comma; Germany&comma; in 2008&comma; and worked to pioneer cancer immunotherapies tailored to individual patients&period;<&sol;p>&NewLine;<p>Their use of mRNA technology came into its own in the pandemic&comma; and the couple said that experience has helped to spur on their work&period;<&sol;p>&NewLine;<p>While conventional vaccines are produced using weakened forms of a virus&comma; mRNAs use only a virus’s genetic code&period;<&sol;p>&NewLine;<p>An mRNA vaccine is injected into the body&comma; where it enters cells and tells them to create antigens which are then recognised by the immune system and prepare it to fight the disease&period;<&sol;p>&NewLine;<p>Asked when cancer vaccines might be accessed by many patients around the world&comma; Prof Sahin said it could happen &OpenCurlyDoubleQuote;before 2030”&period;<&sol;p>&NewLine;<p>Prof Tureci told Kuenssberg&colon; &OpenCurlyDoubleQuote;What we have developed over decades for cancer vaccine development has been the tailwind for developing the Covid-19 vaccine&comma; and now the Covid-19 vaccine and our experience in developing it gives back to our cancer work&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;We have learned how to better&comma; faster manufacture vaccines&period; We have learned in a large number of people how the immune system reacts towards mRNA&period;”<&sol;p>&NewLine;<p>She said the developments have also helped regulators learn about mRNA vaccines and how to deal with them&period;<&sol;p>&NewLine;<p>She added&colon; &OpenCurlyDoubleQuote;This will definitely accelerate also our cancer vaccine&period;”<&sol;p>&NewLine;<p>Taking a positive yet cautious approach&comma; Prof Tureci said&colon; &OpenCurlyDoubleQuote;As scientists we are always hesitant to say we will have a cure for cancer&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;We have a number of breakthroughs and we will continue to work on them&period;”<&sol;p>&NewLine;<p>In August&comma; Moderna said it was suing BioNTech and its partner&comma; US pharmaceutical giant Pfizer&comma; for patent infringement over the company’s Covid-19 vaccine&period;<&sol;p>&NewLine;<p>Asked about that&comma; Prof Sahin said&colon; &OpenCurlyDoubleQuote;Our innovations are original&period; We have spent 20 years of research in developing this type of treatment and of course we will fight for our intellectual property&period;”<&sol;p>&NewLine;&Tab;&Tab;&Tab;<div style&equals;"padding-bottom&colon;15px&semi;" class&equals;"wordads-tag" data-slot-type&equals;"belowpost">&NewLine;&Tab;&Tab;&Tab;&Tab;<div id&equals;"atatags-dynamic-belowpost-68ecec63d756f">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<script type&equals;"text&sol;javascript">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback &equals; function &lpar;&rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; false &equals;&equals;&equals; &lpar; window&period;isWatlV1 &quest;&quest; false &rpar; &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&sol;&sol; Use Aditude scripts&period;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings &equals; window&period;tudeMappings &vert;&vert; &lbrack;&rsqb;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings&period;push&lpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;divId&colon; 'atatags-dynamic-belowpost-68ecec63d756f'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;format&colon; 'belowpost'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; document&period;readyState &equals;&equals;&equals; 'loading' &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;document&period;addEventListener&lpar; 'DOMContentLoaded'&comma; window&period;getAdSnippetCallback &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; else &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback&lpar;&rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<&sol;script>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>


Discover more from London Glossy Post

Subscribe to get the latest posts sent to your email.

- Advertisement -
Exit mobile version